MEN1 and acute myeloid leukemia: Third, different groups independently reported a cooperation between the Menin inhibitors Revumenib, Ziftomenib or Bleximenib and BCL‐2 inhibitor Venetoclax in preclinical models of AML.96, 117, 122, 123